Sepax Light Scattering SEC-MALS Columns 
Certified LS SEC Column with Exceptional Low Shedding & Baseline Noise
Sepax has developed a family of silica-based columns dedicated for SEC-MALS protein/particle applications. These columns provide high resolution, an extended lifetime, excellent lot-to-lot reproducibility, and a full range of pore size selections. Moreover, these columns have exceptionally low light scattering baseline noise and each column is individually QC tested on MALS and delivered with Certificate of Performance.
  • Certified LS SEC columns for optimal light scattering measurements.
  • Exceptional low shedding and low baseline noise
  • Each column individually QC tested on MALS
  • 3um & 5um / wide pore selections (300A, 500A, 1000A, 2000A) for biologics
  • Multi-angle light scattering (MALS) combined with size exclusion chromatography (SEC), is an essential tool for today's protein characterization and can lead to considerably more information about the molecule. 
Applications of SEC-MALS Columns include:
  • Determination of molecular weight, molecular size and molecular structure analysis
  • Determination and quantitation of protein aggregation
  • High resolution separation of biomolecules including MAb, vaccine, VLP
  • Electrostatic aggregation
  • Absolute molecular weight determination
  • Protein formulation stability
  • Liposome/nanoparticle stability and degradation studies
Rituximab SEC Analysis on Triple Detectors - MALS vs UV vs RI
Column: Zenix-C SEC-300 (3 mm, 300 Å), 7.8x 300 mm; Mobile phase: 20 mM sodium phosphate buffer + 700 mM NaCl,  pH 7.0; Flow rate: 1 mL/min;  Detector: UV 280 nm, RI, MALS;  Column temperature: 25 degrees Celcius; Injection volume: 10 mL, 10 mg/mL rituximab

Zoom-in Rituximab SEC Analysis
Column: Zenix -C SEC-300 (3 m m, 3 00 Å), 7.8x 300 mm; 
Mobile phase: 20 mM sodium phosphate buffer + 700 mM NaCl,  pH 7.0;  Flow rate: 1 mL/min;  Detector: UV 280 nm;  
Column temperature: 25 degrees Celcius; 
Injection volume : 10 m L, 10 mg/mL rituximab

Download this application data: 
Rituximab-Light Scattering Results